Novartis släpper efterlängtade resultat inom kronisk myeloisk leukemi på EHA 2016 och visar bredd inom hematologi

På den europeiska hematologikongressen EHA i Köpenhamn 9-12 juni presenterar Novartis viktiga resultat inom flera olika terapiområden. En av höjdpunkterna är data från studier på patienter med kronisk myeloisk leukemi, KML som behandlats med Tasigna (nilotinib).

Bland annat visar resultat från studierna att behandling med nilotinib, hos en undergrupp av patienter med Ph+ KML kan resultera i att sjukdomen stabiliserats på en nivå där behandling inte längre är nödvändig, så kallad treatment free remission.

Kronisk Myeloisk Leukemi, KML

• TFR in pts with CML-CP treated with frontline NIL: Results from the ENESTFreedom study. Abstract #LB618 Saturday, June 11 [5:30 PM–7:00 PM] Poster area (Hall H)
• TFR in pts with CML-CP treated with second-line NIL: First results from the ENESTop study.
• Abstract #LB237 Friday, June 10 [5:15 PM–6:45 PM] Poster area (Hall H)
• Successful TFR in CML after 2 y consolidation with NIL of an MR^4.5 response level achieved originally with IM: First report from STAT2 trial in Japan Abstract #P229 Friday, June 10 [5:15 PM–6:45 PM] Poster area (Hall H)
• Stepwise dose escalation method for nilotinib in STEP STOP TRIAL: A multicenter phase 2 trial Abstract #PB1825

Myeloproliferativa neoplasier, MPN

• 5-Year Final Efficacy and Safety Analysis From COMFORT-I. Abstract #S452 Saturday, June 11 [11:30 AM-11:45 AM] Location: Hall A3
• Ruxolitinib Proves Superior to BAT in Pts With PV and a Nonpalpable Spleen: Results from Ph 3b RESPONSE 2 Study. Abstract #S112 Friday June 10 [12:00 PM-12:15 PM] Location: Auditorium 1
• Ruxolitinib Reduces JAK2V617F Allele Burden in Pts With PV Enrolled in the RESPONSE Study. Abstract #S454 Saturday, June 11 [12:00 PM-12:15 PM] Location: Hall A3

Novartis presenterar också data från flera andra hematologiområden, bland annat idiopatisk trombocytopen purpura, ITP och myelom, samt kliniska resultat från studier med midostaurin.

Idiopatisk trombocytopen purpura, ITP

• Final Safety and Efficacy Results From the EXTEND Study: Treatment With Eltrombopag in Adults With Chronic Immune Thrombocytopenia. Abstract #S517 Saturday, June 11 [4:15 PM−4:30 PM] Room H4
• Thrombopoietin Receptor Agonist Eltrombopag For Advanced MDS or AML and Severe Thrombocytopenia: 12-week, Randomized, Placebo-controlled, Phase 2 ASPIRE Study. Abstract #S130 Friday, June 10 [12:00 PM−12:15 PM] Hall C14
• Safety and Efficacy of Eltrombopag In Splenectomized and Nonsplenectomized Patients With Immune Thrombocytopenia: Results From the EXTEND Study. Abstract #P404 Friday, June 10[5:15 PM–6:45PM] Poster area (Hall H)
• Oral Thrombopoietin Receptor Agonist Eltrombopag Treatment During Induction Chemotherapy for AML: Results of A Randomized, Doubleblind, Phase 2 Study.
• Abstract #P185 Friday, June 10 [5:15 PM–6:45 PM] Poster area (Hall H)
• Modeling and Simulation Support Eltrombopag Dosage Escalation Based on Platelet Count for Pediatric Patients With Persistent or Chronic ITP Abstract #E1420 Thursday, June 9

Akut myeloisk leukemi och akut systemisk mastocytos

• A novel epigenetic resistance mechanism to the FLT inhibitor PKC412 induces cross-resistance to standard chemotherapy in acute myeloid leukemia (AML). Abstract #S460 Saturday, June 11 [12:15 PM-12:30 PM] Hall C13
• Midostaurin (PKC412) in indolent systemic mastocytosis: A phase 2 trial. Abstract #P303 Friday, June 10 [5:15 PM-6:45 PM] Poster Hall (H)

Myelom

• PANORAMA-1 Phase 3 Pt reported outcomes Abstract #PB1957
• Influence of histone deacetylase inhibitors (HDACi’s) on the expression of adhesion molecules and modern target structures in multiple myeloma (MM). Abstract #E1247 Thursday, June 9
• Drug therapies with the novel RNA polymerase I inhibitor CX-5461 improve efficacy in the treatment of multiple myeloma. Abstract #E1240 Thursday, June 9

Kronisk lymfatisk leukemi, KLL

• PROLONG: Cost-Effectiveness of OFA for maintenance in Relapsed CLL. Abstract # P421 Fri, June 10, 5:15 - 6:45 PM Poster area (Hall H)
• HOMER: A Phase III study of OFA vs R in iNHL relapsed after R- therapy: Results of the interim futility analysis. Abstract # P313 Fri, June 10, 5:15 - 6:45 PM
  Poster area (Hall H)